Welcome to our dedicated page for Galectin Therapeutics news (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics stock.
Galectin Therapeutics Inc (NASDAQ: GALT) pioneers novel carbohydrate-based therapies targeting galectin-3 proteins to address fibrotic diseases and cancers. This page serves as the definitive source for verified company announcements, including clinical trial milestones, regulatory updates, and strategic partnerships.
Investors and researchers will discover timely updates on adaptive clinical programs for conditions like MASH cirrhosis, oncology developments, and scientific advancements in galectin inhibition technology. All content is curated to provide actionable insights without speculative commentary.
The repository includes earnings reports, FDA communications, research collaborations, and therapeutic pipeline progress. Bookmark this page for streamlined access to GALT's latest developments in carbohydrate-based drug innovation and fibrotic disease research.
Galectin Therapeutics (NASDAQ: GALT) will present new clinical data from the NAVIGATE trial at the AASLD Liver Meeting 2025 in Washington, DC, November 7-11, 2025. The company will deliver one oral presentation and one poster highlighting belapectin results in MASH cirrhosis and portal hypertension.
Oral: "Belapectin Reduces Liver Stiffness Progression and Prevents Varices at 18 Months" on Nov 10, 2025, 2:00–3:30 PM ET (Abstract 0145). Poster: "Belapectin Maintains a Favorable Trend in Reducing Variceal Development Over 36 Months" on Nov 8, 2025, 8:00 AM–5:00 PM ET (Abstract 2375). Presentations will be viewable by AASLD attendees and posted on the company's Events & Presentations page after the congress.
Galectin Therapeutics (NASDAQ:GALT), a leader in galectin protein-targeted therapeutics, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York. The company's presentation is scheduled for September 8, 2025, at 1:00 PM ET.
CEO Joel Lewis and CMO Dr. Khurram Jamil will be available for one-on-one meetings during the conference. Investors can access the presentation through a live webcast, which will also be archived on the company's investor relations website.
Galectin Therapeutics (NASDAQ:GALT) reported Q2 2025 financial results and provided updates on their NAVIGATE trial for belapectin in MASH cirrhosis patients. The company ended Q2 with $13.8 million in cash and secured an additional $10 million credit line from its chairman in July 2025.
Key financial metrics include a reduced net loss of $7.6 million ($0.12 per share) compared to $12.4 million in Q2 2024, and significantly lower R&D expenses of $3.3 million vs $9.8 million year-over-year. The company presented promising NAVIGATE trial results at EASL 2025, showing sustained efficacy in reducing liver stiffness and fewer patients experiencing clinically meaningful worsening in the belapectin arm.
Galectin Therapeutics (NASDAQ:GALT) has secured a new $10 million unsecured credit line from Richard E. Uihlein, the company's Board Chairman and largest individual stockholder. The financing is expected to cover projected expenditures through June 2026.
The credit line features borrowings at the Applicable Federal Rate plus 2% (currently 6.05%), with principal and interest due September 30, 2026. The notes are convertible to common stock at the closing price on the date of each note (minimum $3.00 per share). Additionally, up to 200,000 stock purchase warrants will be issued ratably with borrowings.
Notably, the maturity dates for $111 million in existing debt from Uihlein, including three $10 million convertible notes and $81 million in credit lines, have been extended to September 30, 2026. The company continues to advance its NAVIGATE trial for belapectin in MASH cirrhosis treatment.
Galectin Therapeutics (NASDAQ:GALT) has announced its upcoming presentation at the EASL 2025 Congress in Amsterdam, Netherlands, scheduled for May 7-10, 2025. The company will deliver a late-breaking oral presentation featuring data from their NAVIGATE study, which evaluates belapectin, a galectin-3 inhibitor, in patients with MASH cirrhosis and portal hypertension.
The presentation, titled 'Belapectin at 2 mg/kg/LBW Reduces Varices Development in MASH Cirrhosis with Portal Hypertension: Results from the NAVIGATE Trial,' will be presented on May 10, 2025. The company continues to analyze biomarker data, including 18-month trial data and results from 57 subjects who completed 36 months of treatment. Additional results are expected in Q2 2025.
Galectin Therapeutics (NASDAQ: GALT) has reported its 2024 financial results and provided updates on its belapectin program for MASH cirrhosis treatment. The NAVIGATE trial's per-protocol analysis showed promising results, with a 68% reduction in new varices incidence in U.S. patients and a 49% reduction in the overall per-protocol population at 2mg dose.
The company reported a net loss of $47.2 million ($0.76 per share) for 2024, compared to $44.5 million in 2023. R&D expenses increased to $36.6 million from $32.1 million in 2023. The company has $15.1 million in cash, plus access to $11 million in credit lines, providing runway through August 2025.
Additional biomarker data is expected in Q2 2025, as the company prepares for discussions with potential partners and the FDA regarding belapectin's development path forward.
Galectin Therapeutics (NASDAQ: GALT) has reported additional results from its NAVIGATE trial for belapectin in patients with MASH cirrhosis and portal hypertension. The analysis revealed a statistically significant 68.1% reduction (p=0.02) in new varices incidence with belapectin versus placebo in U.S. per-protocol patients.
While the trial's initial composite endpoint didn't reach statistical significance in the intent-to-treat population (N=355), the completer population of 287 patients showed a 49.3% reduction in varices incidence (p=0.04). The U.S. subset analysis (n=186) demonstrated stronger results, with only 4 out of 60 belapectin-treated patients developing varices compared to 13 out of 62 in the placebo group.
With an estimated 3 million U.S. adults affected by MASH cirrhosis and clinically significant portal hypertension, for which no FDA-approved therapies exist, the company continues analyzing data, including results from approximately 50 patients who completed 36-months of therapy. Additional data is expected by Q1 2025.